• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Daily low-dose aspirin may help combat cancer
Conclusion The systematic review looked at 47 studies and attempted to combine the results, looking for evidence of a beneficial effect of low-dose aspirin on risk of death in people already diagnosed with cancer. The few RCTs identified – the best-quality evidence – did not provide conclusive evidence that aspirin improves survival rates. The rest of the studies were observational in nature, so cannot prove that aspirin reduces the risk of death from cancer. The only significant results were for a 24% reduction in risk of death from colon cancer, and a possible 11% reduced risk of death from prostate cancer. However,...
Source: NHS News Feed - April 22, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Top 20 Research Studies of 2015 for Primary Care Physicians.
This article, the fifth installment in this annual series, summarizes the 20 POEMs based on original research studies judged to have the greatest clinical relevance for family physicians. Key recommendations include questioning the need for backup throat cultures; avoiding early imaging and not adding cyclobenzaprine or oxycodone to naproxen for patients with acute low back pain; and encouraging patients with chronic or recurrent low back pain to walk. Other studies showed that using a nicotine patch for more than eight weeks has little benefit; that exercise can prevent falls that cause injury in at-risk older women; and ...
Source: American Family Physician - April 30, 2016 Category: Primary Care Authors: Ebell MH, Grad R Tags: Am Fam Physician Source Type: research

Prostate size, nocturia, and the digital rectal exam: a cohort study of 30,500 men
ConclusionsDRE is a modestly accurate tool for measuring prostate volume. While DRE posterior surface area represents a statistically significant predictor of nocturia, the magnitude of effect suggests it has limited clinical utility for assessing this condition, particularly in the presence of cardiovascular risk factors.This article is protected by copyright. All rights reserved.
Source: BJU International - July 31, 2016 Category: Urology & Nephrology Authors: Benjamin V. Stone, Jonathan Shoag, Joshua A. Halpern, Sameer Mittal, Patrick Lewicki, David M. Golombos, Dina Bedretdinova, Bilal Chughtai, Christopher E. Barbieri, Richard K. Lee Tags: Original Article Source Type: research

Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men
ConclusionsDigital rectal examination is a modestly accurate tool for measuring prostate volume. While DRE posterior surface area represents a statistically significant predictor of nocturia, the magnitude of effect suggests it has limited clinical utility for assessing this condition, particularly in the presence of cardiovascular risk factors.
Source: BJU International - August 22, 2016 Category: Urology & Nephrology Authors: Benjamin V. Stone, Jonathan Shoag, Joshua A. Halpern, Sameer Mittal, Patrick Lewicki, David M. Golombos, Dina Bedretdinova, Bilal Chughtai, Christopher E. Barbieri, Richard K. Lee Tags: Original Article Source Type: research

Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: Implications for epidemiological research
Conclusions A variety of sociodemographic, lifestyle and health-related characteristics are associated with PSA testing, suggesting that observed associations of some of these traits with risk for prostate cancer in epidemiological studies may be, at least partially, due to detection bias.
Source: Cancer Epidemiology - September 29, 2016 Category: Cancer & Oncology Source Type: research

Nine Easy Ways to Gain Control of Your Health in Your Forties
What lifestyle changes should you make to stay healthy through your 40s? originally appeared on Quora - the knowledge sharing network where compelling questions are answered by people with unique insights. Answer by Keck Medicine of USC, 500+ internationally renowned doctors at a leading academic medical center, on Quora: Getting older has its perks. Chances are you're more confident, have more direction and a defined sense of self. While your health is likely not a primary concern, it's important to take steps now to stop subtle changes before they become major health issues. Your 40s is the decade that your habits sta...
Source: Healthy Living - The Huffington Post - January 9, 2017 Category: Consumer Health News Source Type: news

Monoclonal Gammopathy of Undetermined Significance - Patient Characteristics and Referral Patterns
ConclusionMGUS is often incidentally detected as part of a work up for other medical conditions, and our results reveal that there is a variety of reasons for which monoclonal testing is performed. With recent developments in our understanding of the significance of monoclonal gammopathy and its association with certain renal and organ damage (Fermand et al., 2018; Leung et al., 2012), there may be a change in how the paraproteinemia investigations are utilized by clinicians in different disciplines. It will be important to recognize and establish appropriate indications for testing. Furthermore, MGUS patients present with...
Source: Blood - November 21, 2018 Category: Hematology Authors: Lee, H., Street, L., Tay, J., Grossman, J., Thaell, J. F., Goodyear, D., McCulloch, S., Duggan, P., Neri, P., Jimenez-Zepeda, V. Tags: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III Source Type: research

Sex Difference of Radiation Response in Occupational and Accidental Exposure
Conclusion and Outlook This review summarizes the data from major human studies on the health risks of radiation exposure and shows that sex can potentially influence the prolonged response to radiation exposure (Figure 1 and Tables 1, 2). These data suggest that long-term radiosensitivity in females is higher than that in males who receive a comparable dose of radiation. Our analysis of the literature agrees with the conclusions of the recent report on the Biological effects of ionizing radiation (BEIR VII) published in 2006 by the National Academy of Sciences (NAS), United States (National Research Council, 2006). The B...
Source: Frontiers in Genetics - May 2, 2019 Category: Genetics & Stem Cells Source Type: research

Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population ‐based propensity score matching study
ConclusionThis nationwide population ‐based study revealed that ADT was not associated with cerebral infarction after adjusting for potential confounders.
Source: Cancer Medicine - June 9, 2019 Category: Cancer & Oncology Authors: Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jae Hyun Bae, Jae Young Park Tags: ORIGINAL RESEARCH Source Type: research

Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients.
Conclusion: Better chronic disease management is needed among prostate cancer survivors through more effective survivorship care planning and interventions that promote health behaviors. PMID: 32269460 [PubMed - in process]
Source: Ethnicity and Disease - April 11, 2020 Category: International Medicine & Public Health Tags: Ethn Dis Source Type: research

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Cardiovascular Complications of Prostate Cancer Therapy
AbstractPurpose of reviewWith treatment advances, the most common cause of death in prostate cancer patients is cardiovascular disease. Discerning the contribution of prostate cancer treatment on cardiovascular complications versus the natural progression of cardiovascular disease remains an ongoing area of investigation. Evaluating the research and identifying opportunities for further investigation is critical for optimal care of this prostate cancer patient population.Recent findingsThe degree that hormone therapy contributes to cardiovascular morbidity and mortality remains uncertain with conflicting results from large...
Source: Current Treatment Options in Cardiovascular Medicine - November 12, 2020 Category: Cardiology Source Type: research

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Pages: 1  2  3